Carolina Reduzzi

Today we launched the "ISLB Global Survey: Oncologist Attitudes and Practices on Liquid Biopsy" to collect worldwide data on the use of liquid biopsy in clinical practice! Help us sharing the survey with all the oncologists you know :) docs.google.com/forms/d/e/1FAI…

🚨 SABCS25 Highlight | PHERGuide (PHERGain translational ctDNA analysis) A major step forward in reshaping early HER2+ breast cancer management. Key findings from this ctDNA-guided translational study: 🔬 Baseline insights: • ctDNA detected in 71% of patients; associated with stage & nodal status. • Baseline ctDNA did NOT predict pCR — reinforcing that tumor biology is dynamic, not static. ⚡ Early treatment dynamics: • ctDNA clearance by C3D1 strongly correlated with pCR (p=0.003). • Early molecular response outperformed baseline biomarkers. 🧬 Pre-surgery signal (most impactful): • 83% achieved ctDNA clearance pre-surgery. • 0% of patients with detectable ctDNA at surgery achieved pCR — a powerful negative predictive marker. • Pre-surgery ctDNA positivity associated with worse 3-year iDFS. 📈 Survival: • Both baseline ctDNA negativity and ctDNA clearance (early & late) predicted significantly better 3-year iDFS. 🌍 Why this matters now: This study strengthens a growing paradigm: ctDNA is emerging as an actionable tool to refine risk stratification, guide treatment escalation/de-escalation, and potentially reshape how we personalize therapy in early HER2+ disease—beyond imaging and pathology. 🔜 Clinical horizon: • Identify high-risk patients who may benefit from novel escalation (e.g., T-DXd strategies). • Support de-escalation trials for early molecular responders. • Integrate methylation-based ctDNA assays into upcoming HER2+ adjuvant/neo-adjuvant designs. An important translational contribution from PHERGain, pointing to the future of molecularly adaptive treatment in HER2+ eBC. @OncoAlert @weoncologists @ReduzziCarol

🚀 Our launch event was a success! It featured an insightful discussion & a deeply moving patient testimonial that underscored the urgency of our mission. 🙌 Thank you for fueling our work! Our momentum continues straight to SABCS! Here our abstracts: pmacgroup.org/post/pmac-at-s…

New Study 👉Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive #MetastaticBreastCancer: A biomarker analysis from the PACE phase II study. #ctDNA #MNC #BreastCancer 📎pubmed.ncbi.nlm.nih.gov/40853871/ @LGerratana @ReduzziCarol @RMJesel @AngieDemichele @jane_meisel @YAbdouMD @KUMedCenter @NaomiKoMD @DrHBurstein @MKDeMeo @stolaney1 @elmayermd

Great paper from our ISLB Young Committee! A huge effort to keep sharing #LiquidBiopsy knowledge through reviews and editorials after major conferences worldwide. Follow us for more LB updates and insights! 🌍🧬 #ISLB #sciencecommunication

DESTINYBreast06 at #ASCO25 suggests a greater benefit from T-DXd in BRCA1/2-mutant #MBC (HR 0.17) ‼️Small N (20 pts) 🧬 biologically plausible synergy via DNA damage. ⚠️ Still no data on key biomarkers like ERBB2 #BreastCancer #ADC #Biomarkers #PrecisionMedicine

If you are a young researcher with an interest in liquid biopsy, come talk to us at the @isliquidbiopsy booth at #ASCO2025 about the activities of the Young Committee and how to join! @robertobore

Here with @drgandara , ISLB CMO, and some amazing members of the ISLB Young Committee! 🙌 Great to meet in person and share ideas 💡on how to keep growing together. Excited for what’s ahead! the best is yet to come! #ASCO25 @Booth12041 @ReduzziCarol @mgoudaMD @RobertoBoreaMD @eleonoranicolo @letipontolillo @shurbisinghal

Super excited to share our latest review in the Journal of Liquid Biopsy on the huge impact of LB in oncology! 🩸🔬 LB is reshaping cancer care💥 👉pubmed.ncbi.nlm.nih.gov/40255897/ @isliquidbiopsy @ReduzziCarol @OSUCCC_James @rolfolab @WeillCornell @UmbertoMalapel1 @ChristianRolfo

🩸👀See how @WCMEnglanderIPM is using #LiquidBiopsy to improve #PrecisionMedicine w/ @HashemAGH @GuardantHealth eipm.weill.cornell.edu/research/resea…

The Liquid Biopsy Platform is launching a new seminar series within the HemOnc Seminar Talk - Carolina Reduzzi (@ReduzziCarol) @WeillCornell oncodaily.com/blog/carolina-… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews

2025 ISLB Annual Congress, will take place in Orlando, Florida, November 1-3, 2025. This is an extraordinary gathering of scientists, clinicians, industry leaders, and innovators, all united by a shared passion for advancing liquid biopsy 2025.islb.info

The International Society of Liquid Biopsy (@isliquidbiopsy) is conducting a global survey on the use of Liquid Biopsy in clinical practice. Your input will help shape strategies to improve its implementation and effectiveness in cancer care worldwide. 🌍 @ReduzziCarol 🔍oncodaily.com/blog/islb-2520… #LiquidBiopsy #OncoDaily #HealthCare #Oncology #Cancer #Health #Medicine #CancerCare #MedTwitter #MedEd #MedOnc #MedNews

Now you can find the link to complete our @isliquidbiopsy survey in the @OncoAlert newsletter! 📨 It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide! bit.ly/43JzN03 @ReduzziCarol @ChristianRolfo @UmbertoMalapel1 @weoncologists

pubmed.ncbi.nlm.nih.gov/39998904/ Our meta-analysis aggregates data from more the 30 studies comprising 3000+ patients, showing that ctDNA decrease and clearance are strongly associated with PFS and OS in lung cancer. Results hold true for targeted treatments and immunotherapy! @iaslc #LCSM @GuardantHealth @LucenceHealth @ASCO @uicc Time is ripe to include as outcome in prospective studies so we can incorporate in decision making and drug approval process - @FDAOncology @JCOGO_ASCO @ASCOPost @JackWestMD @n8pennell @ChristianRolfo @StephenVLiu @myESMO @SylvesterCancer @cancermd @NarjustFlorezMD @Jani_Chinmay @Latinamd

Our new #CTC review is published today via Elsevier. Congrats to the authors @youbin_zhang David Scholten, Wenan Qiang @LeonidasPlatan1 @DrWGradishar @ShanaOKelley @LurieCancer @NUFeinbergMed and @czbiohub Thanks to @ReduzziCarol and @LGerratana authors.elsevier.com/a/1kfqy_i3fF9a…

Survey Participation Request on Behalf of @isliquidbiopsy & @OncoAlert Oncologist Attitudes and Practices on Liquid Biopsy 👉 buff.ly/4kgngY6 This survey aims to evaluate oncologists' attitudes, practices, and barriers to the use of liquid biopsy in clinical care. Your participation in this survey is voluntary. 10-15 minutes in length. @ChristianRolfo @UmbertoMalapel1 @drgandara @DrYukselUrun @CtcLaboratory @mayoccc @HeekeSimon @ElJanLe @MJOSESERRANO19 @LuisRaezMD @aadel_chaudhuri @ReduzziCarol @rolfolab @WeOncologists @RobertoBoreaMD @eleonora_nicolo @AngeloDipa_ @ESaldanhaMD @A_OrtegaFranco @GeorgieDibs @ddemiguelperez @mgoudaMD @RoisinDaly_ @KonVenetis @PasqualePisapia

Happy to have contributed to this work showing the effect of bone metastasis on #HER2 expression and secondary metastatic dissemination in HR+/HER2- metastatic #BreastCancer Out now on @CD_AACR! @CtcLaboratory @WeillCornell @BadoIgor doi.org/10.1158/2159-8…

🗓️Mark Your Calendars! Join us at FOCUS on TOP in Udine, Italy, on March 17-18, 2025! 📍 Venue: Hotel Là di Moret, Udine, Italy 🚆 Train: Udine railway station ✈️ Airports: Venice Marco Polo, Trieste - Friuli Venezia Giulia 🌐 More Info: focusontop.it

🎤 Hear it from our speakers! On March 17, 2025, at 14:00, @ReduzziCarol will take the stage at FOCUS on TOP in the #LiquidBiopsy Session, exploring the role of circulating tumor cells (#CTCs) in #MRD monitoring with #ctDNA. Program and registration: 👇 ecm.meetingsrl.eu/focus_TOP25/de…

You’ve heard me say that #LiquidBiopsies are here to stay. A lot of the talk is about circulating tumor DNA🧬ctDNA. Circulating Tumor Cells➖CTCs🟣🟠🔴 are another less talked about lens🔍. Intact cells➕Membrane🔬. 📕 📖 👇🏽here’s our work as a chapter/article. @OncoAlert 🧵1/